Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ: REVB )

3.270 -0.130 (-3.82%)
Streaming Delayed Price Updated: 3:52 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,896
Open 3.378
Bid (Size) 3.260 (5)
Ask (Size) 3.370 (1)
Prev. Close 3.400
Today's Range 3.260 - 3.420
52wk Range 3.190 - 60.80
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire

Performance

YTD
-68.89%
-68.89%
1 Month
-22.07%
-22.07%
3 Month
-51.34%
-51.34%
6 Month
-77.37%
-77.37%
1 Year
-93.45%
-93.45%

More News

Read More
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
From Revelation Biosciences, Inc.
Via Business Wire
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
Via Chartmill
These stocks are moving in today's session
Via Chartmill
The market is filled with gapping stocks in Tuesday's session.
Via Chartmill
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Revelation Biosciences (REVB) Stock Is Down 38%
Via Benzinga
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
From Revelation Biosciences, Inc.
Via Business Wire
Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results
Via Benzinga
Gold Down Over 1%; US Initial Jobless Claims Increase
Via Benzinga
Dow Jumps 100 Points; BJ's Wholesale Earnings Top Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.